Guggenheim raised the firm’s price target on Immatics (IMTX) to $19 from $16 and keeps a Buy rating on the shares. The firm is updating its model for Q3 results and quarterly trends as well as last week’s clinical update to include probability-adjusted estimates for IMA402 in melanoma and ovarian cancer, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMTX:
- Morning Movers: E.W. Scripps surges after report of Sinclair takeover interest
- Immatics Reports Q3 2025 Financial Results and Business Update
- Immatics reports Q3 EPS (EUR 0.42) vs (EUR 0.08) vs last year
- IMTX Earnings this Week: How Will it Perform?
- Promising Efficacy and Safety of Immatics’ IMA402 and IMA401 Drive Buy Rating